Scientific Advisory Board

Henry S. Friedman, MD

Duke University Medical Center

Dr. Friedman is world’s foremost expert in glioblastomas and Dep Director of Preston Robert Tisch Brain Tumor Ctr. He is involved in the treatment of over 900 glioblastoma patients per year. He was also instrumental in the FDA approval of Avastin which generated $56 Billion for Roche Pharma (2004-2017).

Joyce Ann O’Shaughnessy, MD

Texas Oncology & US Oncology Research

Dr. O’Shaughnessy is one of the top three experts in breast cancer in the United States. She is Co-Chair of Breast Cancer Research, Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center, Chair for The US Oncology Network and member of the Scientific Advisory Board for the US Oncology Research Network.

Armand B. Cognetta Jr, MD

Florida State University

Dr. Cognetta is one of the nation’s leading dermatologists with the largest skin cancer practice in Florida. He is the Assoc. Professor Dermatology at FSU and Clinical Professor and Chief of the Division of Dermatology for FSU. He has supported many FDA drug approval submissions to treat skin cancers and is leading Phase I/II trials for squamous cell cancer, basal cell cancer, actinic keratosis, and sebhorreic keratosis, in a 24 million patient pool

David Ashley, MD, PhD

Duke University Medical Center

Dr. Ashley is one of the global experts in pediatric neuro-oncology and is Director of Pediatric Neuro-Oncology at the Preston Robert Tisch Brain Tumor Ctr. His primary research focus is laboratory based, investigating immunotherapy as a novel approach to treatment of tumors of the central nervous system (CNS). 

Richard W. Joseph, MD

Mayo Clinic

Dr. Joseph is an oncologist for the Division of Hematology/Oncology, Department of Internal Medicine for the Mayo Clinic and is considered one of the best key opinion leaders in melanoma. He is one is of the world’s experts in stem-cell transplantation and cellular therapy.